GUBamy, AbbVie-licensed amylin drug from Gubra, shows 7.8% weight loss in Phase 1 trial, vs 2% weight gain with placebo after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback